Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities. Our development strategy is to tackle different immune escape mechanisms to treat solid tumors in three main areas:
- Boosting immune cell function
- Boosting immune effector cell fitness and persistence, and
- Increasing tumor cell recognition and immunotherapy susceptibility
Essentially, we aim to maximize the power of our INTASYLTM therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.